4
Changes in Ownership
Aurinia Pharmaceuticals Inc. Filed Acc 0001628280-21-020527
EVP of Research sold 130,000 shares at $29.75 ($3,867,500)
- EVP of Research acquired 95,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Huizinga Robert Bindert · EVP of Research
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-10-25 | Exercise or conversion : show line 1 in the form | +95,000 | $3.20 | $304,000 | 195,728 | D |
| 2021-10-25 | Sale : show line 2 in the form | −130,000 | $29.75 | $3,867,500 | 65,728 | D |
| Open-market sales · 130,000 sh · avg $29.75 · $3,867,500 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-10-25 | Exercise or conversion : show line 3 in the form Stock Option (right to buy) | −95,000 | 3,864 | D |
Loading xslF345X03/wf-form4_163528039067523.xml…